- Home
- SGMO vs IXHL Comparison
SGMO vs IXHL Comparison
Compare SGMO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMO | IXHL |
|---|---|---|
| Founded | 1995 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.2M | 134.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMO | IXHL |
|---|---|---|
| Price | $0.40 | $0.29 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 7.8M |
| Earning Date | 03-16-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,875,000.00 | $12,000.00 |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.08 |
| 52 Week High | $1.40 | $2.24 |
Technical Indicators
Market Signals| Indicator | SGMO | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 27.26 |
| Support Level | $0.35 | $0.25 |
| Resistance Level | $0.60 | $0.34 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.29 | 10.06 |
Price Performance
Historical ComparisonAbout SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.